In the same study, SR18292 strongly reduced oxygen consumption rate (OCR) on CML CD34+ without affecting extracellular acidification rate (ECAR) and combination with Nilotinib highly increased apoptosis and reduced clonogenicity of the leukemic cells [14]. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.